Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01709292 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started2012-11-07
View on ClinicalTrials.gov ↗
The goal of this clinical research study is to learn about how vemurafenib may affect certain biomarkers in patients with PTC. Biomarkers are in the blood/tissue and may be related to your reaction to the study drug. The safety of this drug will also be studied. Vemurafenib is designed to block the BRAF gene mutation. This mutation causes cancer and cancer growth. By blocking this mutation, the drug may kill the cancer cells with the mutation and/or stop the tumor from growing.

Amendment history 2 changes detected by DataLookout

2026-09-15
Primary completion pushed: 2026-09-30 → 2028-09-30
2026-09-15
Completion pushed: 2026-09-30 → 2028-09-30
Trial Details
NCT Number NCT01709292
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Genentech, Inc.
Conditions Thyroid Cancer
Enrollment 24 participants
Start Date 2012-11-07
Primary Completion 2028-09-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-09-14